New Phase 3 data from the OptiTROP-Lung06 trial show sacituzumab tirumotecan (sac-TMT) plus pembrolizumab met its PFS endpoint in 1L PD-L1-negative non-squamous NSCLC. Other key topics include the utility of ctDNA for monitoring response to BRAF-MEK inhibitors and ongoing debates around optimal first-line therapy for BRAF V600E-mutant and EGFR-mutant NSCLC.
“the first ADC + ICI regimen globally to succeed in this setting.”
— @chuminhua432 · OptiTROP-Lung06 trial data · View post ↗📌 Amplified by @KolPulseAI
“Can ctDNA be used to monitor pts treated w/ BRAF-MEK inhibitors?”
— @TejasPatilMD · ctDNA in BRAF-mutant NSCLC · View post ↗📌 Amplified by @KolPulseAI
“For newly diagnosed EGFR del 19 mNSCLC, is combination therapy your default over monotherapy?”
— @lungoncdoc · EGFR del 19 treatment strategy · View post ↗The FDA approved @Celcuity’s Revtorpyk (gedatolisib), with fulvestrant and with or without palbociclib, on July 14, 2026 for HR+/HER2−, PIK3CA wild-type locally advanced or metastatic breast cancer that progressed on prior endocrine therapy (VIKTORIA-1, Study 1); the PIK3CA-mutant cohort is not approved (KOL reactions · VIKTORIA-1 trial profile). Separately, updated 15-year SOFT/TEXT results are refocusing the question of the preferred approach for high-risk premenopausal HR+/HER2− early breast cancer.
“Gedatolisib now approved for PIK3CAwt ER+ MBC. Very active regimen, many open questions”
— @PTarantinoMD · Revtorpyk approval · View post ↗
“The @FDA approves gedatolisib as 2nd line therapy in combo with fulvestrant in tumors w/o PIK3CA mutations. Median PFS F, 2.0m, F+G, 7.4m, F+G+palbo 9.3m.”
— @DrHBurstein · Revtorpyk approval · View post ↗
“After the 15-year SOFT/TEXT results, what is your preferred approach for high-risk premenopausal HR+/HER2− early breast cancer?”
— @Dr_Oncologista · SOFT/TEXT Trials · View post ↗A study on a GPC3 CAR-T therapy in heavily pretreated hepatocellular carcinoma (HCC) showed a 44% ORR and 14.2-month median OS. Additionally, a first-of-its-kind study demonstrated the feasibility of a mutant KRAS targeted vaccine in individuals at high risk for pancreatic cancer, with persistent T-cell responses.
“Exciting data for a promising solid tumor CAR target, dominant negative TGFb armored GPC3 CAR published in @Nature today, 44% ORR and 14.2mo mOS in HCC (many of whom were 3L+)”
— @jay_daniels1 · GPC3 CAR-T in HCC · View post ↗
“This is the 1st study to demonstrate the feasibility of mutant KRAS targeted vaccine - not in established #PancreaticCancer - but in HIGH RISK individuals, with persistent T cells ~2years!”
— @Aiims1742 · KRAS vaccine in high-risk individuals · View post ↗Track oncology’s top KOLs in your specialty
Create a free account, pick the tumor types you cover, and go beyond the tweet — the intelligence pharma teams use to map influence and prepare for engagement:
- ✓Enhanced KOL profiles
- ✓Pharma influence & potential advisory-board patterns
- ✓2025 Open Payments financial analysis
- ✓Social-media sentiment & trend signals
Two large randomized Phase 3 studies of perioperative chemo-immunotherapy in Muscle-Invasive Bladder Cancer (MIBC) are set to read out at ESMO26. Discussions also center on treatment strategies for MIBC, including the integration of trimodality therapy as an alternative to radical cystectomy. Additionally, a recent publication highlights the risk of venous thromboembolism in patients with urothelial carcinoma receiving systemic therapy.
“In MIBC, radical cystectomy remains the standard — but not every patient chooses it.”
— @drenriquegrande · MIBC treatment strategy · View post ↗
“The readout of 2 big randomized Ph3 studies of perioperative chemoIO in MIBC is planned in Proffered Paper Session 2, stay tuned!”
— @AndreaNecchi · ESMO26 MIBC data · View post ↗
“Venous thromboembolism in patients with urothelial carcinoma receiving systemic therapy”
— @UrolOncol · VTE in urothelial carcinoma · View post ↗The phase III ENDURANCE (E1A11) trial, published in the NEJM, evaluated lenalidomide maintenance duration. In patients with standard-risk newly diagnosed multiple myeloma not receiving an upfront ASCT, the trial found that continuing lenalidomide maintenance indefinitely provided no overall survival benefit over a limited 2-year duration, while causing more side effects. This result challenges the current standard of continuing maintenance until progression.
“Just out!! In @NEJM - Our randomized trial in myeloma (ENDURANCE trial) shows limited duration of lenalidomide maintenance is just as good as indefinite therapy, with less side effects!!!”
— @VincentRK · ENDURANCE trial results · View post ↗📌 Amplified by @KolPulseAI
“I don't practice myeloma but this is a very meaningful de-escalation trial with immediate global implications. This should set an example for the why and the how of de-escalation trials in oncology.”
— @oncology_bg · De-escalation trials · View post ↗📌 Amplified by @KolPulseAI
“The phase III ENDURANCE trial challenges the default “continue until progression” approach.”
— @DrRishabhOnco · Challenging standard of care · View post ↗
“The ENDURANCE maintenance trial is an important addition to the myeloma literature. Like every randomized trial, however, its findings should be interpreted within the population it studied.”
— @HenrychihangFu1 · Trial interpretation · View post ↗Leukemia trial highlights from EHA2026 include OPTI-AML (14d vs. 28d venetoclax), KOMET-007 (ziftomenib + 7+3), and SENTRY (selinexor + ruxolitinib). Separately, a publication reports real-world outcomes for the CAR T-cell therapy lisocabtagene maraleucel in large B-cell lymphoma.
“3 studies we touched on during our leukemia highlights from @EHA_Hematology #EHA2026 conference with @EuniceWangMD 1. OPTI-AML: 14d vs. 28d Ven (with Aza) 2. KOMET-007: Ziftomenib + 7+3 3. SENTRY: Selinexor + Ruxolitinib”
— @OncBrothers · EHA2026 Leukemia Highlights · View post ↗📌 Amplified by @KolPulseAI
“Real-world outcomes for lisocabtagene maraleucel in patients with relapsed or refractory large B-cell lymphoma”
— @MostafaFaisal14 · Lisocabtagene maraleucel in LBCL · View post ↗
“Lelliott et al. showed that the CDK4/6 inhibitor trilaciclib enhanced the metabolic fitness of and cytotoxicity by human CD19 CAR-T cells while reducing their proliferation in vitro.”
— @ACIR_org · Trilaciclib with CAR-T (preclinical) · View post ↗